Consecutive blood letting and peginterferon alfa-2a/ribavirin standard treatment compared to peginterferon alfa-2a/ribavirin standard treatment alone for treatment-naive patients with hepatitis C virus genotype one and elevated ferritin levels.

Trial Profile

Consecutive blood letting and peginterferon alfa-2a/ribavirin standard treatment compared to peginterferon alfa-2a/ribavirin standard treatment alone for treatment-naive patients with hepatitis C virus genotype one and elevated ferritin levels.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2011

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms KAPRI
  • Most Recent Events

    • 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 30 Jun 2009 Primary endpoint 'Viral-kinetic-parameters' has not been met.
    • 30 Jun 2009 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top